Macrocyclics introduces new products
January 10, 2014
Macrocyclics, Inc. (an AREVA Med company) announced today the introduction of four new products that will expand PET imaging applications with copper-64 and gallium-68 using NOTA-based chelating platforms. In addition, a new serotonin-based DOTA conjugate offers the potential to image serotoninergic neurotransmission using a radioisotope or with gadolinium by magnetic resonance imaging (MRI).
Please visit http://www.macrocyclics.com for detailed information.
AREVA Med: Developing Nuclear Medicine for Tomorrow’s Cancer Treatments
The goal of AREVA Med’s lead-212 research is to create personalized treatments using targeted immunotherapy. Using this biomedical innovation, cancer cells are specifically targeted and destroyed by a vector radiolabeled with lead-212, without harming nearby healthy cells.